Neurocrine Biosciences
Work Here?
About
Company Stage
IPO
Employees
1,001-5,000
Industries
Biotechnology, Healthcare
Total Funding
N/A
Headquarters
San Diego, California
Founded
1992
Simplify's Take
What believers are saying
- CRENESSITY's FDA approval marks a significant advancement in CAH treatment.
- Collaboration with Nxera Pharma strengthens Neurocrine's position in neuropsychiatric therapeutics.
- Participation in major healthcare conferences boosts Neurocrine's visibility and investor relations.
What critics are saying
- Increased competition in muscarinic agonist market may impact Neurocrine's market share.
- Reliance on PANTHERx Rare for distribution poses potential partnership risks.
- High cost of CRENESSITY could limit patient accessibility and market penetration.
What makes Neurocrine Biosciences unique
- CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
- Neurocrine's muscarinic agonist portfolio targets innovative treatments for neuropsychiatric disorders.
- Partnership with Pantherx® Rare enhances patient access to rare disease treatments.
Help us improve and share your feedback! Did you find this helpful?
Benefits
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Parental Leave
Health Insurance
Dental Insurance
Vision Insurance
Paid Holidays
Neurocrine Biosciences is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
💡
We update Neurocrine Biosciences's jobs every 8 hours, so check again soon! Browse all jobs →